Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals | Practical Law

Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals | Practical Law

This Practice Note discusses some key issues to consider when structuring and negotiating an option to acquire a pharmaceutical company, such as purchase price, duration of the option, events triggering the option, the relevant product's development plan and antitrust and accounting implications.

Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals

Practical Law Article 8-525-8887 (Approx. 9 pages)

Using Option Structures to Reduce Buyer Risk in Pharmaceutical M&A Deals

by Krishna Veeraraghavan and Marc A. Morgenthau, Sullivan & Cromwell LLP, with Practical Law Corporate & Securities
Law stated as of 26 Apr 2013 • USA (National/Federal)
This Practice Note discusses some key issues to consider when structuring and negotiating an option to acquire a pharmaceutical company, such as purchase price, duration of the option, events triggering the option, the relevant product's development plan and antitrust and accounting implications.